The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women

Expert Review of Clinical Pharmacology

Volumn 8, Issue 6, 2015, Pages 769-784

  Komm, Barry S ^a   Morgenstern, Diana ^a   Yamamoto, Luis A ^a   Jenkins, Simon N ^a  

^a PFIZER INC   (United States)

Author keywords

bisphosphonates; calcitonin; conjugated estrogens bazedoxifene; denosumab; hormone therapy; postmenopausal osteoporosis; safety; SERMs; strontium ranelate; teriparatide

Indexed keywords

ALANINE AMINOTRANSFERASE; BAZEDOXIFENE PLUS CONJUGATED ESTROGEN; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; ESTROGEN; GAMMA GLUTAMYLTRANSFERASE; GESTAGEN; PARATHYROID HORMONE[1-34]; SALCATONIN; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; TIBOLONE; BONE DENSITY CONSERVATION AGENT;

ACUTE PHASE RESPONSE; AMENORRHEA; ANAPHYLAXIS; ARTHRALGIA; ATRIAL FIBRILLATION; BONE PAIN; BREAST CANCER; BREAST DISEASE; BREAST TENDERNESS; CARDIOVASCULAR DISEASE; CELLULITIS; CEREBROVASCULAR ACCIDENT; CONJUNCTIVITIS; CONTROLLED CLINICAL TRIAL (TOPIC); DEEP VEIN THROMBOSIS; DIARRHEA; DRESS SYNDROME; DRUG SAFETY; DRUG TOLERABILITY; EAR INFECTION; ECZEMA; ENDOCARDITIS; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; EPISTAXIS; ERYSIPELAS; ESOPHAGUS CANCER; ESTROGEN THERAPY; FEMUR SUBTROCHANTERIC FRACTURE; FEVER; FLU LIKE SYNDROME; FRACTURE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; INFECTION; ISCHEMIC HEART DISEASE; JAW OSTEONECROSIS; KIDNEY DYSFUNCTION; LABYRINTHITIS; LEG CRAMP; LUNG EMBOLISM; MASTALGIA; META ANALYSIS (TOPIC); MUSCLE SPASM; MYALGIA; NAUSEA; NEOPLASM; OSTEOSARCOMA; PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; POSTMENOPAUSE OSTEOPOROSIS; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINITIS; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SKIN INFECTION; STEVENS JOHNSON SYNDROME; THROMBOEMBOLISM; TOXIC EPIDERMAL NECROLYSIS; VAGINA BLEEDING; VAGINA DISCHARGE; VENOUS THROMBOEMBOLISM; ADVERSE EFFECTS; COMPLICATION; FEMALE; HORMONE SUBSTITUTION; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PROCEDURES; RISK;

BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; OSTEOPOROTIC FRACTURES; PROGESTINS; RISK;

EID: 84946499575     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2015.1099432     Document Type: Review

References (147)

1. The North American Menopause Society. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17:25-54.
2. National Osteoporosis Foundation. Clinician's guide to prevention and treatment of osteoporosis. Washington (DC): National Osteoporosis Foundation; 2013.
3. International Osteoporosis Foundation. Facts and statistics about osteoporosis and its impact. Nyon (Switzerland): International Osteoporosis Foundation; [updated 2014; cited 2014 Mar 12]. Available from: http://www.iofbonehealth.org/facts-statistics.
4. Bauer RL, Deyo RA. Low risk of vertebral fracture in Mexican American women. Arch Intern Med. 1987;147:1437-1439.
5. Bauer RL. Ethnic differences in hip fracture: a reduced incidence in Mexican Americans. Am J Epidemiol. 1988;127:145-149.
6. Barrett-Connor E, Siris ES, Wehren LE, et al. Osteoporosis and fracture risk in women of different ethnic groups. J Bone Miner Res. 2005;20:185-194.
7. Cauley JA. Defining ethnic and racial differences in osteoporosis and fragility fractures. Clin Orthop Relat Res. 2011;469:1891-1899.
8. ACOG Practice Bulletin N. 129. Osteoporosis. Obstet Gynecol. 2012;120:718-734.
9. Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24:23-57.
10. Arora T, Rehan HS. A perspective on role of calcium and vitamin D in cardiovascular outcomes and lipid profile. J Basic Clin Physiol Pharmacol. 2015;26:427-431.
11. Noguchi Y, Kawate H, Nomura M, et al. Eldecalcitol for the treatment of osteoporosis. Clin Interv Aging. 2013;8:1313-1321.
12. Eriksen EF, Diez-Perez A, Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. Bone. 2014;58:126-135.
13. Freemantle N, Cooper C, Diez-Perez A, et al. Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int. 2013;24:209-217.
14. Shane E, Burr D, Abrahamsen B, et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2014;29:1-23.
15. Schilcher J, Koeppen V, Ranstam J, et al. Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls. Bone. 2013;52:389-392.
16. Meier RP, Perneger TV, Stern R, et al. Increasing occurrence of atypical femoral fractures associated with bisphosphonate use. Arch Intern Med. 2012;172:930-936.
17. Schilcher J, Michaelsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med. 2011;364:1728-1737.
18. Black DM, Kelly MP, Genant HK, et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med. 2010;362:1761-1771.
19. Park-Wyllie LY, Mamdani MM, Juurlink DN, et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA. 2011;305:783-789.
20. Whitaker M, Guo J, Kehoe T, et al. Bisphosphonates for osteoporosis - where do we go from here? N Engl J Med. 2012;366:2048-2051.
21. European Medicines Agency. European Medicines Agency concludes class review of bisphosphonates and atypical fractures. Rare atypical fractures of the femur: a class effect of bisphosphonates [press release]. London: European Medicines Agency; [updated 2011 Apr 15; cited 2013 Oct 29]. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Press-release/2011/04/WC500105281.pdf.
22. Boonen S, Ferrari S, Miller PD, et al. Postmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk - a perspective. J Bone Miner Res. 2012;27:963-974.
23. Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial. JAMA. 2006;296:2927-2938.
24. Dell RM, Adams AL, Greene DF, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone Miner Res. 2012;27:2544-2550.
25. Pazianas M, Kim SM, Yuen T, et al. Questioning the association between bisphosphonates and atypical femoral fractures. Ann N Y Acad Sci. 2015;1335:1-9.
26. Ruggiero S, Dodson TB, Fantasia J, et al. Medication-related osteonecrosis of the jaw - 2014 update. Rosemont (IL): American Association of Oral and Maxillofacial Surgeons; [updated 2014; cited 2015 Mar 27]. Available from: https://www.aaoms.org/docs/position-papers/mronj-position-paper.pdf?pdf=MRONJ-Position-Paper.
27. Rizzoli R, Burlet N, Cahall D, et al. Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis. Bone. 2008;42:841-847.
28. Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356:1809-1822.
29. Black DM, Reid IR, Boonen S, et al. The effect of 3 versus 6 years of zoledronic acid treatment of osteoporosis: a randomized extension to the HORIZON-Pivotal Fracture Trial (PFT). J Bone Miner Res. 2012;27:243-254.
30. Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. Arthritis Rheum. 2006;54:1838-1846.
31. Bianchi G, Czerwinski E, Kenwright A, et al. Long-term administration of quarterly IV ibandronate is effective and well tolerated in postmenopausal osteoporosis: 5-year data from the DIVA study long-term extension. Osteoporos Int. 2012;23:1769-1778.
32. FDA drug safety communication: new contraindication and updated warning on kidney impairment for reclast (zoledronic acid). Silver Spring (MD): Food and Drug Administration; [updated 2011 Sep 1; cited 2015 Mar 12]. Available from: http://www.fda.gov/Drugs/DrugSafety/ucm270199.htm.
33. Pazianas M, Cooper C, Ebetino FH, et al. Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag. 2010;6:325-343.
34. Recker RR, Lewiecki EM, Miller PD, et al. Safety of bisphosphonates in the treatment of osteoporosis. Am J Med. 2009;122:S22-S32.
35. Black DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res. 2015;30:934-944.
36. Lyles KW, Colon-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357:1799-1809.
37. Colon-Emeric CS, Mesenbrink P, Lyles KW, et al. Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res. 2010;25:91-97.
38. Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. N Engl J Med. 2007;356:1895-1896.
39. Howard PA, Barnes BJ, Vacek JL, et al. Impact of bisphosphonates on the risk of atrial fibrillation. Am J Cardiovasc Drugs. 2010;10:359-367.
40. McClung MR, Zanchetta JR, Racewicz A, et al. Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year data. Osteoporos Int. 2013;24:293-299.
41. Reginster JY, Adami S, Lakatos P, et al. Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Ann Rheum Dis. 2006;65:654-661.
42. Bauer DC, Black D, Ensrud K, et al. Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med. 2000;160:517-525.
43. McClung MR, Wasnich RD, Recker R, et al. Oral daily ibandronate prevents bone loss in early postmenopausal women without osteoporosis. J Bone Miner Res. 2004;19:11-18.
44. Fogelman I, Ribot C, Smith R, et al. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. BMD-MN Study Group. J Clin Endocrinol Metab. 2000;85:1895-1900.
45. Mellstrom DD, Sorensen OH, Goemaere S, et al. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;75:462-468.
46. Okolicsanyi L, Dal BN. The gastrointestinal tolerability of bisphosphonates. Aging (Milano). 2001;13:344-346.
47. Tadrous M, Wong L, Mamdani MM, et al. Comparative gastrointestinal safety of bisphosphonates in primary osteoporosis: a network meta-analysis. Osteoporos Int. 2014;25:1225-1235.
48. Fadda V, Maratea D, Trippoli S, et al. Gastrointestinal and renal side effects of bisphosphonates: differentiating between no proof of difference and proof of no difference. J Endocrinol Invest. 2015;38:189-192.
49. Wysowski DK. Reports of esophageal cancer with oral bisphosphonate use. N Engl J Med. 2009;360:89-90.
50. Cardwell CR, Abnet CC, Cantwell MM, et al. Exposure to oral bisphosphonates and risk of esophageal cancer. JAMA. 2010;304:657-663.
51. Green J, Czanner G, Reeves G, et al. Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort. Bmj. 2010;341:c4444.
52. Sieber P, Lardelli P, Kraenzlin CA, et al. Intravenous bisphosphonates for postmenopausal osteoporosis: safety profiles of zoledronic acid and ibandronate in clinical practice. Clin Drug Investig. 2013;33:117-122.
53. Welton JL, Morgan MP, Marti S, et al. Monocytes and gammadelta T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial. J Bone Miner Res. 2013;28:464-471.
54. Severe pain with osteoporosis drugs. Silver Spring (MD): Food and Drug Administration; [updated 2008; cited 2015 Mar 12]. Available from: http://www.fda.gov/downloads/Safety/FDAPatientSafetyNews/UCM417867.
55. McClung MR, Balske A, Burgio DE, et al. Treatment of postmenopausal osteoporosis with delayed-release risedronate 35 mg weekly for 2 years. Osteoporos Int. 2013;24:301-310.
56. Maalouf NM, Heller HJ, Odvina CV, et al. Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature. Endocr Pract. 2006;12:48-53.
57. Joffe HV. Calcitonin salmon for the treatment of postmenopausal osteoporosis [oral presentation]. Silver Spring (MD): Food and Drug Administration; [updated 2013 Mar 5; cited 2015 Mar 11]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ReproductiveHealthDrugsAdvisoryCommittee/UCM343748.pdf.
58. Food and Drug Administration. Questions and answers: changes to the indicated population for miacalcin (calcitonin-salmon). Silver Spring (MD): Food and Drug Administration. [updated 2014 Mar 11; cited 2015 Mar 11]. Available from: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm388641.htm.
59. Fortical [package insert]. Maple Grove (MN): Upsher-Smith Laboratories, Inc.; 2014.
60. Miacalcin injectable [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2015.
61. Miacalcin Nasal Spray [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corporation; 2014.
62. Overman RA, Borse M, Gourlay ML. Salmon calcitonin use and associated cancer risk. Ann Pharmacother. 2013;47:1675-1684.
63. Forteo [package insert]. Indianapolis (IN): Eli Lilly and Company; 2012.
64. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-1441.
65. Lindsay R, Scheele WH, Neer R, et al. Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis. Arch Intern Med. 2004;164:2024-2030.
66. Osteosarcoma data in patients treated with FORTEO. Indianapolis (IN): Eli Lilly and Company; updated 2012 Sep 24; cited 2015 Mar 13]. Available from: https://www.lillymedicalanswers.com/Forteo/Pages/osteosarcoma-data.aspx.
67. Baron R, Hesse E. Update on bone anabolics in osteoporosis treatment: rationale, current status, and perspectives. J Clin Endocrinol Metab. 2012;97:311-325.
68. Miller PD. Safety of parathyroid hormone for the treatment of osteoporosis. Curr Osteoporos Rep. 2008;6:12-16.
69. Prolia [package insert]. Thousand Oaks (CA): Amgen Inc.; 2015.
70. Anastasilakis AD, Toulis KA, Polyzos SA, et al. Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab. Ther Clin Risk Manag. 2012;8:295-306.
71. Cummings SR, San MJ, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009;361:756-765.
72. Xue F, Ma H, Stehman-Breen C, et al. Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia(R) (denosumab) for the treatment of postmenopausal osteoporosis. Pharmacoepidemiol Drug Saf. 2013;22:1107-1114.
73. Watts NB, Roux C, Modlin JF, et al. Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? Osteoporos Int. 2012;23:327-337.
74. Zhou Z, Chen C, Zhang J, et al. Safety of denosumab in postmenopausal women with osteoporosis or low bone mineral density: a meta-analysis. Int J Clin Exp Pathol. 2014;7:2113-2122.
75. McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821-831.
76. Bone HG, Chapurlat R, Brandi ML, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab. 2013;98:4483-4492.
77. Protelos [summary of product characteristics]. London: European Medicines Agency; [updated 2014; cited 2015 March 3]. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000560/WC500045525.pdf.
78. Kanis JA, Johansson H, Oden A, et al. A meta-analysis of the effect of strontium ranelate on the risk of vertebral and nonvertebral fracture in postmenopausal osteoporosis and the interaction with FRAX®. Osteoporos Int. 2011;22:2347-2355.
79. Cacoub P, Descamps V, Meyer O, et al. Drug rash with eosinophilia and systemic symptoms (DRESS) in patients receiving strontium ranelate. Osteoporos Int. 2013;24:1751-1757.
80. Assessment report for protelos and osseor. London: European Medicine Agency; [updated 2012 May 25; cited 2015 Mar 10]. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Assessment-Report---Variation/human/000560/WC500131789.pdf.
81. Cianferotti L, D'Asta F, Brandi ML. A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis. Ther Adv Musculoskelet Dis. 2013;5:127-139.
82. European Medicines Agency recommends that protelos/osseor remain available but with further restrictions. London: European Medicines Agency; [updated 2014 Feb 21; cited 2015 Apr 6]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/news-and-events/news/2014/02/news-detail-002031.jsp&mid=WC0b01ac058001d126.
83. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310:1353-1368.
84. Chlebowski RT, Anderson GL, Gass M, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA. 2010;304:1684-1692.
85. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003;362:419-427.
86. Whitehead M, Farmer R. The million women study: a critique. Endocrine. 2004;24:187-193.
87. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause. 2010;17:242-255.
88. Hickey M, Agarwal S. Bleeding with menopausal hormone therapy. Best Pract Res Clin Obstet Gynaecol. 2009;23:141-149.
89. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA. 2007;297:1465-1477.
90. Cordina-Duverger E, Truong T, Anger A, et al. Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLoS One. 2013;8:e78016.
91. Smith NL, Blondon M, Wiggins KL, et al. Lower risk of cardiovascular events in postmenopausal women taking oral estradiol compared with oral conjugated equine estrogens. JAMA Intern Med. 2014;174:25-31.
92. Shufelt CL, Merz CN, Prentice RL, et al. Hormone therapy dose, formulation, route of delivery, and risk of cardiovascular events in women: findings from the Women's Health Initiative Observational Study. Menopause. 2014;21:260-266.
93. Olie V, Canonico M, Scarabin PY. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol. 2010;17:457-463.
94. Renoux C, Dell'aniello S, Garbe E, et al. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. Bmj. 2010;340:c2519.
95. Sweetland S, Beral V, Balkwill A, et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost. 2012;10:2277-2286.
96. Cummings SR, Ettinger B, Delmas PD, et al. The effects of tibolone in older postmenopausal women. N Engl J Med. 2008;359:697-708.
97. Kenemans P, Bundred NJ, Foidart JM, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. Lancet Oncol. 2009;10:135-146.
98. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2005;365:1543-1551.
99. Formoso G, Perrone E, Maltoni S, et al. Short and long term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2012;2:CD008536.
100. Christodoulakos GE, Botsis DS, Lambrinoudaki IV, et al. A 5-year study on the effect of hormone therapy, tibolone and raloxifene on vaginal bleeding and endometrial thickness. Maturitas. 2006;53:413-423.
101. Saeideh Z, Raziyeh M, Soghrat F. Comparing the effects of continuous hormone replacement therapy and tibolone on the genital tract of menopausal women; a randomized controlled trial. J Reprod Infertil. 2010;11:183-187.
102. Livial [United Kingdom package insert]. Hertfordshire (UK): Merck Sharp & Dohme; 2013.
103. Delmas PD, Ensrud KE, Adachi JD, et al. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial. J Clin Endocrinol Metab. 2002;87:3609-3617.
104. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008;23:1923-1934.
105. Palacios S, Silverman SL, De Villiers TJ, et al. A 7-year randomized, placebo-controlled trial assessing the long-term efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: effects on bone density and fracture. Menopause. 2015;22:806-813.
106. Kanis JA, Johansson H, Oden A, et al. Bazedoxifene reduces vertebral and clinical fractures in postmenopausal women at high risk assessed with FRAX. Bone. 2009;44:1049-1054.
107. Christiansen C, Chesnut CH III, Adachi JD, et al. Safety of bazedoxifene in a randomized, double-blind, placebo- and active-controlled Phase 3 study of postmenopausal women with osteoporosis. BMC Musculoskelet Disord. 2010;11:130.
108. Martino S, Disch D, Dowsett SA, et al. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin. 2005;21:1441-1452.
109. Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125-137.
110. Palacios S, De Villiers TJ, Nardone FC, et al. Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study. Maturitas. 2013;76:81-87.
111. Ethun KF, Wood CE, Cline JM, et al. Endometrial profile of bazedoxifene acetate alone and in combination with conjugated equine estrogens in a primate model. Menopause. 2013;20:777-784.
112. Lewis-Wambi JS, Kim H, Curpan R, et al. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor alpha and cyclin D1. Mol Pharmacol. 2011;80:610-620.
113. Duavee [package insert]. Philadelphia (PA): Wyeth Pharmaceuticals Inc, A Subsidiary of Pfizer Inc.; 2013.
114. Lindsay R, Gallagher JC, Kagan R, et al. Efficacy of tissue-selective estrogen complex of bazedoxifene/conjugated estrogens for osteoporosis prevention in at-risk postmenopausal women. Fertil Steril. 2009;92:1045-1052.
115. Pinkerton JV, Harvey JA, Lindsay R, et al. Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: a randomized trial. J Clin Endocrinol Metab. 2014;99:E189-E198.
116. Komm BS, Thompson JR, Mirkin S. Cardiovascular safety of conjugated estrogens plus bazedoxifene: meta-analysis of the SMART trials. Climacteric. 2015;16:1-19.
117. Pickar JH, Yeh IT, Bachmann G, et al. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. Fertil Steril. 2009;92:1018-1024.
118. Guidance for Industry. Estrogen and estrogen/progestin drug products to treat vasomotor symptoms and vulvar and vaginal atrophy symptoms - recommendations for clinical evaluation. Silver Spring (MD): Food and Drug Administration; [updated 2003; cited 2014 Jan 6]. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071643.pdf.
119. Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women. London: European Medicines Agency; [updated 2006 May 1; cited 2014 May 19]. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003348.pdf.
120. Harvey JA, Pinkerton JV, Baracat EC, et al. Breast density changes in a randomized controlled trial evaluating bazedoxifene/conjugated estrogens. Menopause. 2013;20:138-145.
121. Pinkerton JV, Harvey JA, Pan K, et al. Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial. Obstet Gynecol. 2013;121:959-968.
122. Lobo RA, Pinkerton JV, Gass ML, et al. Evaluation of bazedoxifene/conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile. Fertil Steril. 2009;92:1025-1038.
123. Pinkerton JV, Utian WH, Constantine GD, et al. Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene/conjugated estrogens: a randomized, controlled trial. Menopause. 2009;16:1116-1124.
124. Wright NC, Looker AC, Saag KG, et al. The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. J Bone Miner Res. 2014;29:2520-2526.
125. Burge R, Dawson-Hughes B, Solomon DH, et al. Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. J Bone Miner Res. 2007;22:465-475.
126. Stone KL, Seeley DG, Lui LY, et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res. 2003;18:1947-1954.
127. Siris ES, Chen YT, Abbott TA, et al. Bone mineral density thresholds for pharmacological intervention to prevent fractures. Arch Intern Med. 2004;164:1108-1112.
128. Gehlbach S, Hooven FH, Wyman A, et al. Patterns of anti-osteoporosis medication use among women at high risk of fracture: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). PLoS One. 2013;8:e82840.
129. Silverman S, Christiansen C. Individualizing osteoporosis therapy. Osteoporos Int. 2012;23:797-809.
130. Balasubramanian A, Tosi LL, Lane JM, et al. Declining rates of osteoporosis management following fragility fractures in the U.S., 2000 through 2009. J Bone Joint Surg Am. 2014;96:e52.
131. Wysowski DK, Greene P. Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012. Bone. 2013;57:423-428.
132. Steinkellner AR, Denison SE, Eldridge SL, et al. A decade of postmenopausal hormone therapy prescribing in the United States: long-term effects of the Women's Health Initiative. Menopause. 2012;19:616-621.
133. Ameye L, Antoine C, Paesmans M, et al. Menopausal hormone therapy use in 17 European countries during the last decade. Maturitas. 2014;79:287-291.
134. Edwards BJ, Bunta AD, Lane J, et al. Bisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) project. J Bone Joint Surg Am. 2013;95:297-307.
135. Felsenberg D, Silman AJ, Lunt M, et al. Incidence of vertebral fracture in Europe: results from the European Prospective Osteoporosis Study (EPOS). J Bone Miner Res. 2002;17:716-724.
136. Chapurlat RD. Treatment of postmenopausal osteoporosis with odanacatib. Expert Opin Pharmacother. 2014;15:559-564.
137. Bone HG, Dempster DW, Eisman JA, et al. Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial. Osteoporos Int. 2015;26:699-712.
138. McClung MR, Langdahl B, Papapoulos S, et al. Odanacatib antifracture efficacy and safety in postmenopausal women with osteoporosis: results from the phase III long-term odanacatib fracture trial (LOFT) [abstract OC1]. Osteoporos Int. 2015; 26(suppl 1): OC1.
139. Merck announces data from pivotal phase 3 fracture outcomes study for odanacatib, an investigational oral, once-weekly treatment for osteoporosis. Kenilworth (NJ). [updated 2014 Sep 15; cited 2015 Mar 15]. Available from: http://www.mercknewsroom.com/news-release/research-and-development-news/merck-announces-data-pivotal-phase-3-fracture-outcomes-st.
140. Lippuner K. The future of osteoporosis treatment - a research update. Swiss Med Wkly. 2012;142:w13624.
141. Cosman F, Lane NE, Bolognese MA, et al. Effect of transdermal teriparatide administration on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2010;95:151-158.
142. Hammerle SP, Mindeholm L, Launonen A, et al. The single dose pharmacokinetic profile of a novel oral human parathyroid hormone formulation in healthy postmenopausal women. Bone. 2012;50:965-973.
143. Henriksen K, Andersen JR, Riis BJ, et al. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis. Bone. 2013;53:160-166.
144. Leder BZ, O'Dea LS, Zanchetta JR, et al. Effects of abaloparatide, a human parathyroid hormone-related Peptide analog, on bone mineral density in postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2015;100:697-706.
145. McClung MR, Grauer A, Boonen S, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370:412-420.
146. Recker RR, Benson CT, Matsumoto T, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015;30:216-224.
147. Evenepoel P, D'Haese P, Brandenburg V. Romosozumab in postmenopausal women with osteopenia. N Engl J Med. 2014;370:1664.